Imcheck Closes Upsized Eur 96 Million (Usd 103 Million) Financing To Advance Clinical Program Of First-In-Human Gamma-Delta T Cell Activating Antibody And Accelerate Development Of Disruptive Immunotherapeutic Pipeline
Imcheck Closes Upsized Eur 96 Million (Usd 103 Million) Financing To Advance Clinical Program Of First-In-Human Gamma-Delta T Cell Activating Antibody And Accelerate Development Of Disruptive Immunotherapeutic Pipeline
06/13/22, 1:00 AM
Location
marseilleMoney raised
€96 million
Marseille, France, June 13, 2022 – ImCheck Therapeutics announced today the close of a EUR 96 million (USD 103 million) financing, co-led by Earlybird and Andera Partners. The Series C round (EUR 80 Million - USD 86 Million) and the last outstanding tranche of Series B converted in Series C shares (EUR 16 Million - USD 17.2 Million) solidifies ImCheck’s financial position and leadership in the gamma-delta T cell space. Invus and The Leukemia & Lymphoma Society Therapy Acceleration Program® also joined the round as new investors. Existing investors including the Growth Opportunity Fund of founding investor Kurma Partners, Eurazeo, Gimv, EQT Life Sciences (previously LSP), Boehringer Ingelheim Venture Fund, Pfizer Ventures, Bpifrance through its Innobio 2 and Large Venture funds, Wellington Partners, Agent Capital, Pureos Bioventures and Alexandria Venture Investments participated.
Company Info
Location
marseille, provence alpes côte d'azur, france
Additional Info
We at Andera Partners are confident the company will move its groundbreaking technology forward to meet patients’ needs in a range of cancer indications with wider potential for auto-immune and infectious diseases.” Responsible and committed, the management company regularly forms partnerships with non-profit sector entities and takes concrete action in the fight against global warming.